Corneal Versus Conjunctival Delivery Using a Delivery Device

This study has been withdrawn prior to enrollment.
Information provided by:
Pfizer Identifier:
First received: September 1, 2005
Last updated: March 4, 2015
Last verified: March 2015
Compare the antihypertensive efficacy of three methods for installing Xalatan

Condition Intervention Phase
Glaucoma, Open-Angle
Ocular Hypertension
Drug: Xalatan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • IOP level in the study eye

Secondary Outcome Measures:
  • Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period

Enrollment: 0

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria:

  • History of closed/barely open anterior chamber angle or a history of angle closure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00143429

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information Identifier: NCT00143429     History of Changes
Other Study ID Numbers: A6111127 
Study First Received: September 1, 2005
Last Updated: March 4, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Primary Open Angle Glaucoma

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Glaucoma processed this record on May 24, 2016